Across TCGA pan-cancer cohorts, GPATCH3 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated GPATCH3 data layer compared with 20 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher GPATCH3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated GPATCH3 expression acts as an unfavorable survival marker.

SCLC and LUAD are the cancer types where GPATCH3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	OS	Median	II,III,IV	0.192	0.699	.002	18	view →
LUAD	DFS	Median	II,III,IV	0.098	0.651	.001	3	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: GPATCH3 tumor-vs-normal RNA expression · all GPATCH3 data types